Semaglutide

Semaglutide is a GLP-1 receptor agonist - a synthetic version of a hormone your gut naturally releases after eating. It mimics the GLP-1 hormone to slow gastric emptying, reduce appetite, and improve blood sugar, which together create a sustained reduction in caloric intake that most people cannot achieve through willpower alone. It is sold under the brand names Ozempic and Wegovy and is FDA-approved, one of the most clinically validated weight-loss medications available today. The primary use is fat loss and metabolic health. Semaglutide is a strong match for people whose main goals are losing body fat and supporting long-term metabolic health - particularly those who have struggled to sustain calorie deficits with diet and exercise alone. It is taken as a once-weekly subcutaneous injection, on the same day each week. Starting dose is 0.25 mg and titration progresses gradually up to a maximum of 2.4 mg, depending on response. Dosing is guided by how your body responds, not by sex. The slow titration is intentional - it keeps GI side effects manageable. The most common side effects are nausea and gastrointestinal upset, particularly early in titration. Semaglutide is not appropriate for people who are pregnant or who have a personal or family history of medullary thyroid cancer. It should not be combined with other GLP-1 agonists such as tirzepatide, retatrutide, or liraglutide. Treatment is ongoing and requires clinical supervision. It is not a short cycle - patients continue under a clinician's care for as long as the therapy is appropriate. Exact starting dose, titration schedule, and duration are set with a licensed provider in the PepDepo network at your consult.